Respiratory DiseaseNCT04361669
Hospice Quality Score Assessment Post Pharmacist Intervention
An observational study of Respiratory Disease and Cardiovascular Diseases, run by Tabula Rasa HealthCare at 1 site in United States.
Trial summary
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores. Read more about this study
- Who is it for?
- Ages 18 to 88 years
- Conditions the study is for
- Respiratory Disease, Cardiovascular Diseases, Neurologic Disorder
- What is being tested?
- Medication safety review
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Apr 2020to 1 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 88 years
- All sexes
- Adult, Older adult
Study population: Study population will be hospice population who received services for 6-months (e.g., between April 2020 to October 2020) and information including: age (excluding patients 89 years or older), gender, medication risk score, NQF score, HCAHPS score, time to fill medication order set, type of chronic condition, and number of medications will be studied.
Who may be able to join
- Adult patients who were referred to hospice by a healthcare provider
Who cannot join
- Patients 89 years or older
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessing the Impact of Pharmacist Interventions on Hospice Quality Scores
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.
Read the detailed description
The objective of this study is evaluate a program at a hospice involving activities designed to improve the site's National Quality Forum (NQF) and Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. These scores are calculated by the hospice using existing patient satisfaction survey scores (HCAHPS). The institution quantifies their compliance with national quality metrics (NQF) and reports this existing data to the pharmacist providing counseling services to their patients. The pharmacist assesses for areas for improvement and provides additional counseling services to improve the continuity and quality of care. The pilot program is scheduled to launch April 2020 and the researchers will look to assess for changes in the NQF scores, HCAHPS scores, and time for their partnering pharmacy to refill the first set of prescriptions.
- Being tested
- Medication safety review
- Keywords
- National Quality Forum Score, HCAHPS, Medication refill, Number medications
- Medical subject headings
- Respiration Disorders, Cardiovascular Diseases, Nervous System Diseases, Dementia, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medication safety reviewOther
Implementation of a medication safety review using a clinical decision support system
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Patients that receive pharmacist-delivered services in the pilot program Receives: Other: Medication safety review | |
| Control | Patients that do not receive pharmacist-delivered services in the pilot program Receives: Other: Medication safety review |
What is being measured
The primary outcome is the main question the study is designed to answer.
National Quality Forum Score
Performance metric used by hospice. Scale 0 - 100 (0=min; 100-high)
Measured: 6 months
Consumer Assessment of Healthcare Providers and Systems
Performance metric used by hospice (0=min; 100-high)
Measured: 6 months
Time to refill
Time to refill prescription from hospice organization (0=min; 100-high)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2020
- Study start22 Apr 2020
- Primary completion1 Sep 2022 (estimated)
- Study completion1 Sep 2022
Why it stopped: Change in study personnel and sponsor.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tabula Rasa HealthCare
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jennifer Bingham, PharmD, Principal investigator, Tabula Rasa HealthCare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04361669
- Sponsor's protocol ID
- TRHC_RD_Hospice_2020
- Status last verified
- Sep 2022
- First submitted
- 22 Apr 2020
- Last updated
- 7 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Impact of Pharmacist Interventions on Hospice Quality Scores
- ClinicalTrials.gov ID
- NCT04361669
- Acronym / sponsor ID
- TRHC_RD_Hospice_2020
- Keywords
- National Quality Forum Score, HCAHPS, Medication refill, Number medications
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Change in study personnel and sponsor.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Tabula Rasa HealthCareIndustry (pharma, biotech, devices)
- Study start
- 22 Apr 2020 (actual)
- Primary completion
- 1 Sep 2022 (estimated)
- Study completion
- 1 Sep 2022 (actual)
- First posted
- 24 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.
Detailed description
The objective of this study is evaluate a program at a hospice involving activities designed to improve the site's National Quality Forum (NQF) and Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores. These scores are calculated by the hospice using existing patient satisfaction survey scores (HCAHPS). The institution quantifies their compliance with national quality metrics (NQF) and reports this existing data to the pharmacist providing counseling services to their patients. The pharmacist assesses for areas for improvement and provides additional counseling services to improve the continuity and quality of care. The pilot program is scheduled to launch April 2020 and the researchers will look to assess for changes in the NQF scores, HCAHPS scores, and time for their partnering pharmacy to refill the first set of prescriptions.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | – | Other: Medication safety reviewPatients that receive pharmacist-delivered services in the pilot program |
| Control | – | Other: Medication safety reviewPatients that do not receive pharmacist-delivered services in the pilot program |
Who may qualify
- Ages
- 18 to 88 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Study population will be hospice population who received services for 6-months (e.g., between April 2020 to October 2020) and information including: age (excluding patients 89 years or older), gender, medication risk score, NQF score, HCAHPS score, time to fill medication order set, type of chronic condition, and number of medications will be studied.
Key inclusion criteria (1 listed)
- Adult patients who were referred to hospice by a healthcare provider
Key exclusion criteria (1 listed)
- Patients 89 years or older
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medication safety reviewImplementation of a medication safety review using a clinical decision support system | Other | Control, Intervention |
Primary outcome
National Quality Forum Score
Time frame: 6 months
Performance metric used by hospice. Scale 0 - 100 (0=min; 100-high)
Consumer Assessment of Healthcare Providers and Systems
Time frame: 6 months
Performance metric used by hospice (0=min; 100-high)
Time to refill
Time frame: 6 months
Time to refill prescription from hospice organization (0=min; 100-high)
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Sep 2022.
- Individual participant dataSharing planned: No
Related trials for Respiratory Disease
RecruitingObservational study
Collection of Lung Fluid and Tissue Samples for Research
Leukocyte Disorders, Respiratory Tract Diseases
Active, not recruitingObservational study
Gulf Long-Term Follow-Up Study
Cardiovascular Disease, Hematologic Diseases
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruitingPhase 2
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Tract Diseases, Neoplasms
RecruitingObservational study
POS-ARI-ER Observational Study of Acute Respiratory Infections
Acute Respiratory Infection, Acute Respiratory Tract Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jennifer Bingham, PharmD principal investigator
Tabula Rasa HealthCare
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Disease and Cardiovascular Diseases, run by Tabula Rasa HealthCare at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
National Quality Forum Score (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022; AzTrials last refreshed its copy on 30 Oct 2026.